The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone ...

Treatment with Cyramza plus Lonsurf did not improve overall survival compared with Lonsurf alone in heavily pretreated ...

and Eli Lilly’s anti-VEGF drug Cyramza (ramucirumab) – in advanced solid tumours. The pharma group licensed ex-China rights to tusamitamab ravtansine from Chinese biotech Innovent in 2017 ...

Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II drugs for Esophageal Cancer have a 25% phase transition ...

Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase II for Thymic Carcinoma. According to GlobalData, Phase II drugs for Thymic Carcinoma does not have sufficient ...

Furthermore, a late-phase trial evaluating Evorpacept in combination with Trastuzumab, Ramucirumab, and Paclitaxel for the treatment of HER2+ gastric cancer is also under progress. A number of other ...

There was a top-line data readout in July from one of these trials, dubbed ASPEN-06, comparing evorpacept plus Genentech's HER2 inhibitor Herceptin (trastuzumab), Eli Lilly's VEGFR2 agonist Cyramza ...

Emibetuzumab, an anti-c-Met bivalent antibody that works by inhibiting the ligand-dependent and ligand-independent initiation of c-Met/HGF signaling, was evaluated for safety and efficacy in ...

All these drugs are given orally. Cyramza (ramucirumab) is a monoclonal antibody classified as targeted therapy and given by infusion, usually every two weeks. Keytruda (pembrolizumab) and Opdivo ...